Ardelyx ($ARDX): Record Q2 Revenue, So What Still Limits IBSRELA?

01 Bull Case, Base Case and Bear Case

Bull Case

The bull case is that IBSRELA is still early in a durable adoption curve, 2026 guidance proves conservative, and the product moves toward management’s long-term blockbuster target without requiring unsustainable promotional spending. XPHOZAH stabilizes despite reimbursement friction and becomes a profitable second revenue stream. ACCEL progresses cleanly, produces positive Phase 3 data in 2027, and supports an sNDA that expands IBSRELA into CIC. RDX10531 gives investors a credible next-generation platform story. Operating leverage improves as revenue scales, and the market begins valuing Ardelyx as a durable commercial biopharma rather than a volatile small-cap biotech.

Base Case

The base case is more moderate. IBSRELA continues growing but requires heavy SG&A support. XPHOZAH remains useful but does not return to the 2024 trajectory. ACCEL remains on track, but its value is discounted until data. Ardelyx maintains a reasonable cash position while continuing to report losses for some time. The stock trades around quarterly execution, guidance credibility, prescription trends and broader biotech risk appetite. In this scenario the shares would likely continue to trade on quarterly execution, because the fundamental story would be improving gradually rather than resolving at once.

Bear Case

The bear case is that IBSRELA growth slows before the cost base shows leverage, XPHOZAH remains constrained by payer access, and management keeps spending aggressively to defend growth and build pipeline. ACCEL could be delayed, fail to meet endpoints or produce data that are not commercially compelling enough to justify expansion. Debt, equity compensation and future share issuance could weigh on per-share value. In that scenario, Ardelyx would still have real products, but the stock could struggle because commercial revenue alone would not be enough to satisfy investors looking for profitability and cleaner capital structure.

What Would Falsify This Reading

Ardelyx today is a company with two selling products, a revenue line that is still growing, a reimbursement problem it has already had to guide down for, and a new lawsuit about how it described all of that. Five things would show that reading to be wrong, and each is checkable against a filing or a company release.

• IBSRELA lands outside the reduced guidance range. Full-year 2026 guidance for IBSRELA was cut to $350 to $370 million on August 6, 2026 after a first half that delivered $86.2 million in the second quarter alone. A third-quarter report that puts the franchise on track for the upper end, or one that forces a second cut, would settle the argument this page leaves open about whether the access problem is temporary or structural.
• XPHOZAH reimbursement changes in either direction. The product’s position depends on coverage policy and on dialysis-provider economics rather than on its mechanism. A favourable policy decision, or a further narrowing of coverage, would move the revenue base without any change in the clinical evidence.
• The securities complaint produces a judgment or a settlement. Broadwater v. Ardelyx, filed on September 17, 2026, alleges disclosure failures about product growth and payer barriers. The allegations are unproven and a lead-plaintiff deadline of November 16 is a procedural step, not a hearing. A dismissal, a settlement or an adverse ruling would each replace an open risk with a number.
• The debt stops being comfortable. Cash and investments were $281.8 million at June 30, 2026 against contractual principal of $250.0 million under the SLR facility after the June 29 Term F draw. That is a secured, variable-rate obligation. A quarter in which the cash balance falls materially towards the drawn principal would change the balance-sheet reading of this page.
• ACCEL, or the rest of the pipeline, becomes a dated event. ACCEL topline is company guidance for the second half of 2027 with no day attached, and RDX10531 has no announced filing. A registered trial timetable, an investigational new drug application or a readout would turn the pipeline from optionality into something that can be valued.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

03 September 23, 2026 update

The latest material development identified is the September securities action. The operating baseline remains the August 6 Q2 disclosure: growing product sales alongside a lower IBSRELA outlook and reimbursement constraints.

The newly filed action is distinct from the earlier securities and derivative cases, all of which have ended. According to the Q2 Form 10-Q, the Yarborough class action over the July 2024 XPHOZAH add-on payment announcement was dismissed with prejudice on December 24, 2025, and the plaintiffs’ appeal was voluntarily dismissed on March 26, 2026; the related derivative case was dismissed by stipulation on April 9, 2026. As of June 30, 2026 the company reported no pending litigation reasonably expected to have a material adverse effect, a statement made before the new complaint was filed. It adds litigation uncertainty, not proof that the allegations are true. Cash and other figures in this snapshot carry their own stated dates; later market data and the two readings of the August 6 disclosure appear in the October 5 section.

Counsel notices concern the same action

September 17–22, 2026 — Levi & Korsinsky announced the action and a November 16 lead-plaintiff motion deadline. Subsequent law-firm reminders are not separate clinical or commercial developments. Source

04 August 6, 2026 Update: Record Revenue, and a Guidance Cut That Came With It

The largest quarter in company history, reported alongside lower expectations

Ardelyx reported second-quarter 2026 results on August 6. Total product revenue was $118.1 million, up 31% year over year and the largest quarterly revenue in the company’s history. IBSRELA contributed $86.2 million, up 33%, and XPHOZAH $31.9 million, up 27%. Cash, cash equivalents and investments stood at $281.8 million as of June 30, against $264.7 million at the end of 2025.

In the same release the company revised its outlook. Full-year 2026 IBSRELA guidance was cut to $350 million to $370 million from $410 million to $430 million. XPHOZAH guidance was reiterated at $110 million to $120 million. Operating expense guidance was revised to below $500 million. The long-term target of $1 billion in IBSRELA revenue remains in place, but the company said it is evaluating evolving market dynamics and their impact on the timing of that achievement. The long-term XPHOZAH guidance was withdrawn outright.

The stated cause is not demand. Chief Executive Mike Raab described IBSRELA demand as strong, with revenue below expectations because of significantly increased utilization management processes from payors — prior authorisations, step edits and similar access controls — which the company says it is actively addressing. Total prescriptions and refills reached the highest demand quarter to date. The gap, in other words, sits between prescriptions written and prescriptions paid.

That distinction matters for how the cut should be read. A demand problem questions whether physicians want the drug. An access problem questions how much of the demand converts into revenue, and it is in principle reversible — but only on the payors’ timetable, not the company’s. Management reiterated that it is moving toward profitability in 2027.

June 29 financing changed the capital-structure discussion

On June 29, Ardelyx received $50.0 million from the Term F tranche of its SLR loan facility. The company said the proceeds were drawn for general corporate purposes and to enhance flexibility for strategic initiatives. The Term F loan matures on July 1, 2030, permits interest-only payments until maturity and bears interest at 4.55% plus the greater of the one-month SOFR reference rate or 3.5%.

Ardelyx had $200.0 million of principal outstanding under the facility at March 31, 2026. Adding the Term F draw brings drawn principal to $250.0 million on a contractual basis after June 29, before considering any repayment or other change not yet reported. The borrowing improves liquidity flexibility but also raises interest expense, secured-debt exposure and the importance of showing that commercial investment can generate sufficient cash returns.

Governance also moved from proposal to fact. At the June 16 annual meeting, shareholders approved a 9.0 million-share increase to the company’s equity-incentive-plan reserve. The vote was 77.4 million shares for and 69.7 million against, with approximately 0.7 million abstentions and 41.4 million broker non-votes. Approval does not mean that all 9.0 million shares will be issued immediately, but it expands the pool available for future awards and strengthens the dilution-monitoring case.

The current watchlist is therefore wider than product revenue alone: IBSRELA prescription quality and guidance, XPHOZAH payer mix and paid prescriptions, ACCEL enrollment progress, RDX10531 IND timing, cash burn, interest expense, use of the new debt proceeds and management’s path toward cash-flow improvement.

Information as of September 5, 2026; Q2 results were published August 6.

05 Executive Summary

Ardelyx is one of those biotech stories that changed shape in public. For years, the company was mainly a development-stage name built around tenapanor, a locally acting NHE3 inhibitor designed to alter intestinal transport pathways. Since the 2023 XPHOZAH approval, Ardelyx has been a commercial-stage biopharmaceutical company with two U.S.-approved products that share the same active ingredient: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH for adults with chronic kidney disease on dialysis who need help reducing serum phosphorus as add-on therapy after inadequate response or intolerance to phosphate binders.

The important part of the story is that the market can no longer analyze Ardelyx like a pure clinical catalyst trade. The old question was whether regulators would accept the tenapanor value proposition. The new question is whether Ardelyx can convert a differentiated mechanism into durable commercial scale, sustainable revenue quality and, eventually, a business model that investors can value on more than peak-sales hope. That transition is rarely clean. It forces traders to look at quarterly product revenue, prescription pull-through, payer friction, selling expenses, cash burn, debt, share-based compensation and management’s ability to fund expansion without destroying per-share value.

XPHOZAH is the more complicated commercial asset. It is scientifically interesting because it attacks phosphate absorption through a differentiated mechanism, and its approval followed a long regulatory path that included a formal dispute resolution process, advisory committee support and final FDA approval in October 2023. However, the commercial story became harder after Medicare Part D coverage changes and broader reimbursement questions. XPHOZAH generated $160.9 million of revenue in 2024 but $103.6 million in 2025, before management guided to $110 million to $120 million in 2026. That does not make the asset irrelevant; it makes it a reimbursement-sensitive franchise that needs to be monitored differently from IBSRELA.

The pipeline beyond the current labels adds optionality rather than immediate certainty. ACCEL, the Phase 3 chronic idiopathic constipation study, is the most important development program because it could expand IBSRELA into a large adjacent constipation population. The trial is designed as a multicenter, randomized, double-blind, placebo-controlled study of tenapanor administered twice daily for 26 weeks in approximately 700 adult CIC patients. Ardelyx expects to complete enrollment by the end of 2026, and topline data are expected in the second half of 2027. If successful, Ardelyx intends to submit a supplemental NDA for CIC. The company is also advancing RDX10531, a next-generation NHE3 inhibitor that is in IND-enabling studies; the February 2026 annual release targeted an IND submission in the second half of 2026, but the first- and second-quarter releases no longer repeat that timing.

The capital structure has become more important. Ardelyx drew an additional $50.0 million term loan on June 29, taking drawn principal under the SLR facility from $200.0 million at March 31 to $250.0 million after the draw. The financing provides additional flexibility for commercial and pipeline spending, but it also raises the hurdle for operating leverage and makes interest expense, secured-debt covenants and capital allocation more relevant to common shareholders.

The bottom line is balanced. Ardelyx has approved products, real revenue and a meaningful commercial platform, but the company remains loss-making, carries more drawn debt and has expanded its equity-award capacity. The bullish case depends on IBSRELA becoming a large and durable GI franchise, XPHOZAH stabilizing despite payer constraints, ACCEL creating a credible label-expansion path and operating leverage becoming visible. The bear case is that revenue growth remains expensive, XPHOZAH never fully recovers, CIC takes longer or disappoints, and debt plus equity compensation reduce per-share value creation.

06 Quick Snapshot

07 ARDX Revenue Growth in One Chart

The clearest visual change in the Ardelyx story is the rise of IBSRELA and the sharp reset in XPHOZAH after its exceptionally strong first full commercial year. The chart uses reported U.S. net product revenue and stops at 2025 for the annual series; the second quarter of 2026, reported on August 6, added $118.1 million of product revenue, of which $86.2 million from IBSRELA and $31.9 million from XPHOZAH.

Source: Ardelyx 2023, 2024 and 2025 annual financial results and SEC filings. Figures are U.S. net product revenue.

08 2026 Guidance: How High Is the Commercial Bar?

Each product is shown on its own scale so the chart measures the operating hurdle rather than simply comparing the absolute size of the two brands. The green band marks management’s full-year 2026 guidance range; the solid bar is 2025 actual revenue.

Source: Ardelyx FY 2025, Q1 2026 and Q2 2026 financial releases. Percentages are simple comparisons between 2025 actual revenue and the published 2026 guidance endpoints; half-year figures are the sum of reported quarters.

09 Company Overview: What Ardelyx Actually Is

Ardelyx is a commercial-stage biopharmaceutical company focused on medicines that address gastrointestinal and cardiorenal-related unmet needs through mechanisms discovered and developed by the company. Its central scientific platform is tenapanor, a minimally absorbed, first-in-class, oral small molecule that inhibits sodium/hydrogen exchanger 3, or NHE3, on the apical surface of the small and large intestines. Because the molecule acts locally in the gastrointestinal tract, the company has been able to develop the same active ingredient across two very different commercial settings.

The first setting is IBS-C, where IBSRELA is approved for adults. This is the cleaner consumer-facing and prescriber-growth story. IBS-C is a chronic condition, patients often cycle through therapies, and a differentiated mechanism can matter if clinicians see real-world benefit, tolerability and refill persistence. Ardelyx has repeatedly emphasized growth across total writers, new prescriptions, refill prescriptions and prescription pull-through. Those are the right commercial indicators to watch because reported revenue can be affected by channel dynamics, gross-to-net adjustments and payer mix. Durable demand needs to appear in the behavior of physicians and patients, not only in a quarterly sales line.

The second setting is hyperphosphatemia in adults with CKD on dialysis, where XPHOZAH is approved as add-on therapy for patients who have an inadequate response to phosphate binders or are intolerant of any dose of phosphate binder therapy. This is a very different market. It is medically serious, specialist-driven, heavily shaped by dialysis economics and reimbursement rules, and more exposed to policy changes. XPHOZAH’s mechanism is distinctive because it reduces phosphate absorption by blocking a paracellular pathway rather than simply adding another binder burden. However, a differentiated mechanism does not automatically translate into frictionless reimbursement. That tension is central to the ARDX story.

Ardelyx’s corporate strategy now has four layers. First, drive IBSRELA growth as the lead franchise. Second, maintain and rebuild XPHOZAH commercial momentum in a difficult access environment. Third, expand tenapanor’s potential through ACCEL in chronic idiopathic constipation and pediatric work. Fourth, use the commercial infrastructure, cash position and NHE3 know-how to build a broader pipeline, including RDX10531. This is the right strategic architecture for a company that wants to evolve beyond a single-product biotech, but it also raises the cost base. A larger commercial and development organization has to be paid for before the market can see the full benefit of scale.

That is why the stock is best viewed as a commercial execution story with embedded clinical optionality. The company has already crossed the line that many small biotechs never cross: it has approved products and meaningful revenue. But it has not yet crossed the next line, which is becoming a self-funding, consistently profitable commercial biopharma business. In between those two stages, volatility is normal. Investors debate not only the size of the opportunity, but the cost of reaching it.

10 The Long Ardelyx Timeline

IBSRELA was approved for the treatment of adults with irritable bowel syndrome with constipation. The approval established tenapanor as a regulatory asset, although the U.S. commercial launch came later.

Ardelyx’s hyperphosphatemia program faced a difficult FDA path. The company pursued formal dispute resolution and continued to argue that tenapanor offered a differentiated mechanism for CKD patients on dialysis. This period created the first major ARDX comeback narrative.

The FDA’s Office of New Drugs granted Ardelyx’s appeal following advisory committee support, reopening the path to resubmission and eventual approval.

XPHOZAH was approved to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy after inadequate response to phosphate binders or intolerance to any dose of binder therapy. Ardelyx became a two-product commercial company.

Ardelyx reported $333.6 million in total revenue, including $158.3 million from IBSRELA and $160.9 million from XPHOZAH. It was the year the company began to look less like a binary FDA story and more like an emerging commercial platform.

XPHOZAH entered the ESRD Prospective Payment System, and Medicare Part D coverage was no longer available. The policy change materially altered the commercial trajectory and made reimbursement an operating issue rather than a theoretical risk.

IBSRELA revenue rose to $274.2 million, up 73% from 2024. XPHOZAH revenue was $103.6 million, down from 2024, while total revenue increased to $407.3 million.

Ardelyx dosed the first patient in ACCEL, a Phase 3 study of tenapanor in chronic idiopathic constipation. The study is designed to enroll approximately 700 adults, with enrollment completion expected by year-end 2026 and topline data expected in the second half of 2027.

Q1 product revenue was $93.4 million, up 38% year over year. IBSRELA reached $70.1 million, up 58%, while XPHOZAH contributed $23.3 million. Cash and investments stood at $238.1 million, and the company reiterated full-year product guidance.

Ardelyx presented a post hoc analysis from NORMALIZE and OPTIMIZE supporting that tenapanor decreased serum phosphate without clinically meaningful changes in measured serum electrolytes other than phosphate and without significant changes in selected nutrition markers, body mass or blood pressure in the analyzed open-label datasets. The update supported the clinical file but did not remove reimbursement friction.

Management participated in a fireside chat at the Jefferies Global Healthcare Conference, keeping commercial execution, pipeline progress and capital allocation in front of institutional healthcare investors.

Stockholders approved a 9.0 million-share increase to the equity incentive plan reserve. The proposal passed with 77.4 million votes for and 69.7 million against, making equity compensation and dilution discipline an important governance watch item.

The company received $50.0 million under its SLR facility for general corporate purposes and strategic flexibility. The tranche matures July 1, 2030, is interest-only until maturity and carries a variable rate equal to 4.55% plus the greater of one-month SOFR or 3.5%.

Ardelyx scheduled its second-quarter results and business update for August 6, 2026, with a conference call at 4:30 p.m. Eastern Time.

11 IBSRELA: The Growth Franchise

IBSRELA is the asset that currently defines the bullish ARDX story. It has a clear approved indication, a large addressable adult IBS-C population, a differentiated mechanism and accelerating reported revenue. The commercial message from management is that growth is coming from multiple demand indicators: more prescribers, more new prescriptions, more refills and better prescription pull-through. That matters because a brand can show early growth from sampling, channel stocking, launch enthusiasm or gross-to-net movement, but a durable chronic therapy needs repeat behavior.

IBSRELA generated $86.2 million in Q2, but the August 6 full-year guidance was reduced to $350–370 million. The $1 billion long-term ambition remains, with its timing under review; The previous 2029 timing is no longer reaffirmed. XPHOZAH retains $110–120 million for 2026, while its long-term forecast was withdrawn.

The important question is not whether IBSRELA grew. It clearly did. The better question is what kind of growth it is. If the growth is mainly the result of broadening prescriber adoption and deeper use among existing writers, the franchise becomes more valuable. If the growth requires disproportionate selling expense, copay support, rebating or aggressive patient assistance, the quality of revenue is lower. Ardelyx’s 10-K reminds investors that product revenue is reported net of estimates for discounts, chargebacks, rebates, wholesaler and GPO fees, copay assistance and returns. That does not mean the revenue is weak. It means investors need to monitor gross-to-net adjustments because they shape how much economic value the top line really creates.

The IBS-C market is attractive because symptoms can be persistent and quality-of-life impact can be high. Many patients have tried other approaches, and clinicians often need alternatives. Tenapanor’s mechanism is different from traditional laxative approaches because it inhibits NHE3 in the gut, reducing sodium absorption and increasing intestinal fluid content. The commercial challenge is that “different” must translate into physician confidence, patient persistence and payer acceptance. A differentiated mechanism wins only if it becomes part of real prescribing habits.

ACCEL adds a second layer to the IBSRELA discussion. Chronic idiopathic constipation is adjacent to IBS-C but not identical. It is a large market, and Ardelyx has stated that CIC affects more than 34 million Americans. If ACCEL succeeds and leads to an sNDA, IBSRELA’s addressable market could expand materially. But this should remain an option, not the base proof. The current investment case still depends first on the approved IBS-C franchise delivering against 2026 guidance and showing that the company can scale the brand without spending indefinitely ahead of revenue.

12 XPHOZAH: Differentiated Science, Harder Commercial Path

XPHOZAH is the more complicated half of Ardelyx. Scientifically, it remains important. The drug was approved as a first-in-class phosphate absorption inhibitor for adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or are intolerant of any dose of phosphate binder therapy. It blocks phosphate absorption locally in the gut through NHE3 inhibition and offers a twice-daily tablet approach. For patients dealing with high pill burden and persistent hyperphosphatemia, the clinical logic is easy to understand.

The regulatory history also matters. XPHOZAH was not an easy approval. The program went through FDA pushback, formal dispute resolution and advisory committee review. In November 2022, the Cardiovascular and Renal Drugs Advisory Committee voted nine to four that the benefits of XPHOZAH outweighed its risks as monotherapy and ten to two, with one abstention, that benefits outweighed risks in combination with phosphate binders. The FDA later approved XPHOZAH in October 2023 with a label as add-on therapy for a defined adult CKD-on-dialysis population.

That history created a strong shareholder narrative: Ardelyx fought through a difficult process and eventually won. But regulatory victory did not remove the reimbursement problem. Dialysis economics are heavily policy-driven, and in 2024 Ardelyx sued HHS and CMS over the plan to include oral-only phosphate-lowering therapies such as XPHOZAH in the ESRD Prospective Payment System bundle. The company argued that the policy would negatively affect access and patient choice. Regardless of legal details, the investment lesson is straightforward: XPHOZAH is a product where payment structure can matter almost as much as clinical differentiation.

The revenue pattern shows that tension. XPHOZAH generated $2.5 million in 2023 after launch, then $160.9 million in 2024, then $103.6 million in 2025. Management has guided to $110 million to $120 million in 2026. This is not the kind of smooth ramp investors usually want from a newly approved product, but the context is unusual. The company has pointed to increased paid prescriptions and non-Medicare use, while also acknowledging access issues. For traders, the right interpretation is not simply “failed launch” or “hidden blockbuster.” It is a reimbursement-sensitive commercial asset with differentiated clinical logic and a narrower near-term path than IBSRELA.

In a bull scenario, XPHOZAH stabilizes, grows gradually among non-Medicare and clinically convinced prescribers, and remains a valuable second revenue stream while IBSRELA carries the main growth burden. In a bear scenario, access friction keeps XPHOZAH from scaling, revenue remains capped, and the company’s nephrology commercial effort absorbs resources without delivering the return investors expected after FDA approval. The current guide suggests management is not asking investors to model explosive near-term growth from XPHOZAH. It is asking them to believe the asset can remain relevant while the broader company builds around IBSRELA.

The next public data on XPHOZAH are scientific rather than financial. On October 5, 2026 Ardelyx announced three posters at ASN Kidney Week 2026 in Denver (October 21–25), all scheduled for Friday, October 23, 10:00 a.m.–12:00 p.m. MDT: FR-PO0317, on real-world serum phosphate outcomes with tenapanor according to existing phosphate-binder use; FR-PO0324, the results of an online survey of patient perspectives on hyperphosphatemia management in end-stage kidney disease; and FR-PO0316, on morbidity and mortality risks associated with cumulative hyperphosphatemia in US dialysis patients. Source Only the first poster is about XPHOZAH itself, and it is observational. The other two describe the disease and its management. They can support the medical argument for better phosphate control, which matters for a product whose challenge is reimbursement and prescribing access, but they do not change the label, the Medicare payment framework or the guidance.

13 May 2026 XPHOZAH Safety Update: Helpful, But Not a Reimbursement Cure

The May 2026 NKF update is worth including because it supports the clinical credibility of XPHOZAH at a time when the commercial debate remains dominated by access. Ardelyx presented a post hoc analysis evaluating the long-term impact of XPHOZAH on serum electrolytes and selected nutrition biomarkers using data from the NORMALIZE 18-month extension study and the OPTIMIZE 26-week open-label study. According to the company, tenapanor treatment reduced serum phosphate without clinically meaningful changes in measured serum electrolytes other than phosphate reduction, and without significant changes in nutrition markers, body mass or blood pressure.

This is supportive for physicians and for the medical narrative around the product, especially because dialysis patients with hyperphosphatemia can be medically complex and often carry a high treatment burden. However, the investment conclusion should remain disciplined. Safety-supportive poster data do not automatically restore Medicare economics, do not remove bundle-related pressure and do not guarantee acceleration in paid prescriptions. The value of this update is that it strengthens the product-support file; it does not independently transform the 2026 revenue guide.

For the stock, this distinction is important. A weak or confusing safety signal would be damaging for a reimbursement-challenged product because it would add medical doubt on top of payer friction. A supportive safety analysis helps remove one layer of concern, but the market will still judge XPHOZAH mainly through paid-prescription growth, payer mix, non-Medicare uptake, dialysis-provider behavior and management’s access commentary in quarterly updates.

14 Financial Snapshot, New Debt and the Operating-Leverage Test

Ardelyx’s financial profile is better than that of a pre-revenue biotech but still not simple. In 2025, total revenue increased to $407.3 million from $333.6 million in 2024. IBSRELA and XPHOZAH together generated $377.8 million in net product sales. That is meaningful commercial scale and gives the company more strategic options than a development-stage issuer.

The second quarter of 2026 extends that scale and sharpens the cost question at the same time. Product revenue of $118.1 million came with research and development expense of $26.1 million, up from $15.7 million a year earlier on investment in the ACCEL Phase 3 trial in chronic idiopathic constipation, and selling, general and administrative expense of $101.4 million, up from $84.0 million. The company describes the SG&A increase as deliberate investment to address access barriers and drive future adoption of IBSRELA — which is to say, the same payor problem that caused the guidance cut is also the reason spending rose.

Net loss narrowed rather than widened: $16.7 million, or $0.07 per share, against $19.1 million and $0.08 per share a year earlier, including $15.3 million of share-based compensation. Revised operating expense guidance of below $500 million for the full year now sits alongside product revenue guidance of $460 million to $490 million once the two brands are combined. That is a narrower gap than it looks, and it is the arithmetic behind management’s stated path to profitability in 2027 — a path that depends on the access barriers easing rather than on further cost reduction.

At the same time, the company remains in investment mode. Q1 2026 product revenue was $93.4 million, but Ardelyx still reported a quarterly net loss of $37.6 million. Selling, general and administrative expense was $102.3 million, and research and development expense was $20.2 million. These spending levels reflect two commercial products and Phase 3 expansion work, but they are also why the market keeps asking when revenue growth will convert into sustained cash generation.

The debt burden is now materially larger

The Q2 10-Q reports $250 million drawn principal at June 30 out of a $300 million facility, with the remaining $50 million Term G loan available at the company’s election until December 20, 2026. Future payments excluding interest total $260.8 million, including contractual final fees, due July 1, 2030. Principal, accounting carrying value ($251.823 million) and total repayments are different measures.

Two pieces of arithmetic, both Merlintrader calculations, show what the facility costs and where its covenant bites. The rate cannot fall below 8.05%, the 4.55% margin plus the 3.5% SOFR floor, so $250 million of principal carries at least about $20.1 million of cash interest a year before fees. The single financial covenant requires trailing six-month net product revenue plus pledged unrestricted cash and cash equivalents to cover 100% of principal. First-half product revenue was $211.5 million, so at $250 million of principal the company needed at least about $38.5 million of qualifying cash on top; if Term G is drawn, the requirement rises to about $88.5 million. Cash and cash equivalents were $97.2 million at June 30, while the $184.6 million of short-term investments do not automatically count. Q2 Form 10-Q, Note 8 →

This does not automatically signal financial distress. Management described the borrowing as strategic flexibility, and the company has a growing commercial revenue base. But the draw increases secured obligations, future interest expense and the importance of understanding what return the company expects from the capital.

Stock-based compensation and the equity-plan expansion remain relevant for per-share analysis. Ardelyx recorded $48.962 million of stock-based compensation expense in 2025. Shareholders approved the addition of 9.0 million shares to the incentive-plan reserve in June 2026. Those shares are not the same as an immediate public offering, but they increase potential future dilution through employee, officer and director awards.

The August 6 report should therefore be read through four linked questions: Is product revenue tracking guidance? Is SG&A becoming more efficient? How much cash was used in Q2? Why did management choose to add debt before the quarter-end report, and how will the proceeds be deployed?

15 Cash Versus Drawn Debt: The New Balance-Sheet Tension

The latest reported liquidity is $281.830 million at June 30: $97.191 million cash and equivalents plus $184.639 million short-term investments. It includes the June financing. H1 operating cash use was $38.636 million, so the increase in liquidity is not proof of operating cash generation.

The split between the two quarters is uneven. Operating activities used $32.2 million in the first quarter, so the second quarter alone used about $6.4 million, a Merlintrader calculation on the cumulative figures. The 10-Q attributes the lower first-half cash use mainly to the timing of payments and inventory purchases, partly offset by the timing of customer collections, so one quarter of near break-even operating cash flow is not yet a trend. Financing provided a net $55.2 million in the half: $48.0 million of net loan proceeds, which combine the $50.0 million Term F draw with the April refinancing of earlier tranches into a new Term H loan net of repayments, fees and costs, plus $7.1 million from employee equity plans. No shares were sold under the $100 million at-the-market program through June 30. SEC XBRL cash-flow data →

16 ACCEL and the CIC Expansion Opportunity

ACCEL is the most important clinical program in the current ARDX setup. It is not an immediate readout, but it is the clearest way for Ardelyx to expand the IBSRELA story beyond the current IBS-C label. The study is designed to evaluate tenapanor in adults with chronic idiopathic constipation, a condition characterized by difficult, infrequent or incomplete bowel movements and significant quality-of-life impact. Ardelyx estimates the U.S. CIC population at more than 34 million people.

The design matters. ACCEL is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of tenapanor administered twice daily for 26 consecutive weeks in approximately 700 adult patients with CIC. The company describes the primary endpoint as patient-reported outcomes in constipation; the trial registry gives the detail. ACCEL (TEN-03-301, NCT07382167) randomizes patients to three doses of tenapanor, 5 mg, 25 mg or 50 mg twice daily, or to placebo, with an estimated 692 participants. The primary endpoint is a durable complete spontaneous bowel movement (CSBM) response: a weekly CSBM response in at least 9 of the first 12 weeks of treatment and in at least 3 of the last 4 of those 12 weeks. The study started on January 13, 2026, lists 109 locations, and in the Q2 Form 10-Q the company said it had initiated all pre-identified sites. Ardelyx expects to complete enrollment by the end of 2026, with topline data expected in the second half of 2027. If successful, Ardelyx intends to submit a supplemental NDA for the CIC indication. The registry’s own dates, an estimated primary completion on February 26, 2027 and study completion on June 4, 2027, are sponsor estimates that were last updated in June 2026; the company’s guidance for topline data remains the second half of 2027.

Pediatric work runs alongside ACCEL. A four-week dose-ranging study of tenapanor in IBS-C patients aged 6 to under 12 (NCT06553547, 72 participants) is listed as completed on July 7, 2026, and a longer safety study in patients aged 6 to under 18 is enrolling by invitation. The company says these trials could potentially provide six months of additional patent life for tenapanor; no pediatric results have been reported. ACCEL registry record → pediatric dose-ranging record →

For traders, ACCEL creates a long-duration catalyst rather than a near-term binary. The trial can support sentiment as enrollment updates arrive, especially if management communicates confidence and keeps timelines intact. But the true value inflection is likely closer to data. Until then, ACCEL remains a credible expansion option attached to a commercial base, not a guaranteed future label.

The strategic logic is strong. IBSRELA is already approved in an adult constipation-related GI condition, and tenapanor has a mechanistic rationale in bowel-movement dynamics. A positive CIC outcome could broaden prescriber conversations and reinforce Ardelyx’s GI franchise. It could also make the long-term $1 billion IBSRELA revenue ambition more plausible. However, CIC is competitive, patient-reported endpoints can be demanding, and payer behavior for a broader indication may not perfectly match the IBS-C experience. The trial adds upside, but it also adds cost and execution risk.

Past conferences and future clinical windows

Past scheduled conferences: Citi investor meetings September 9; Cantor fireside chat September 10 at 11:30 ET / 17:30 CEST; Morgan Stanley September 16 at 07:45 ET / 13:45 CEST. ACCEL enrollment completion remains guided for year-end 2026 and topline for H2 2027. RDX10531 remains in IND-enabling studies in the latest release; the earlier H2 2026 IND target was not repeated there.

September conferences

17 RDX10531 and Pipeline Optionality

RDX10531 is an early but strategically important program because it signals that Ardelyx does not want to be valued forever as a two-brand tenapanor company. Management describes RDX10531 as a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. In its February 19, 2026 annual release the company said it was completing preclinical work ahead of an IND submission in the second half of 2026, with a Phase 1 trial to follow. The first-quarter release of April 30 and the second-quarter release of August 6, like the Q2 Form 10-Q, describe RDX10531 only as “currently being tested in IND-enabling studies” and give no submission date. Until the company restates a date, the second-half 2026 IND is an earlier target rather than current guidance. Q2 2026 release →

The market should not overvalue RDX10531 at this stage. Before an IND, before human safety data and before a defined registration path, it remains early optionality. Even so, the program can contribute to Ardelyx’s long-term strategic value if IBSRELA grows, XPHOZAH stabilizes and ACCEL progresses. If the commercial business disappoints, early pipeline assets will not be enough to carry the valuation.

The key question is capital allocation. Ardelyx has to decide how much to spend on new pipeline formation while still proving that the existing commercial business can scale efficiently. Investors usually reward pipeline expansion when the base business is healthy. They become less patient when the base business is still loss-making and the company keeps adding programs. RDX10531 is therefore a watch item for strategy, not only science.

18 Patent Protection, Orange Book Positioning and Why IP Matters

The tenapanor story is not limited to a near-term commercial launch. In February 2026, the company announced that the U.S. Patent and Trademark Office had issued U.S. Patent No. 12,539,299, titled “Oral Formulations of Tenapanor.” Ardelyx stated that the patent covers the commercial formulations of both IBSRELA and XPHOZAH, has an expiration date of November 26, 2042, and is listed in the FDA Orange Book for both products.

For investors, this does not eliminate commercial risk. Patent life is not the same thing as revenue certainty, and Orange Book listings can still be challenged. But the 2042 formulation patent is important because it extends the conversation beyond a simple short-window launch thesis. A company with two approved products, a growing IBSRELA franchise, a Phase 3 label-expansion program and a longer IP runway can be valued differently from a biotech facing an imminent loss-of-exclusivity wall.

The right way to interpret the IP point is balanced. It supports the durability of the tenapanor platform if the products continue to grow, but it does not solve payer access, SG&A intensity, XPHOZAH reimbursement or clinical execution in CIC. In other words, IP helps protect the opportunity; execution still has to create the value.

19 Management, CEO Background and Governance Watch

PM360 awards recognize leadership, podcast and marketing team — September 30, 2026. The winners were announced at the September 29 PM360 gala. This is a limited corporate and organizational update. It adds no new sales result, label expansion, reimbursement decision, financing or clinical endpoint and does not alter the dated financial or pipeline assumptions set out above. Ardelyx release, September 30, 2026 (GlobeNewswire)

A commercial-leadership change was disclosed after the second-quarter report. In a Form 8-K filed on August 17, 2026, Ardelyx said that Eric Foster notified the company on August 11 of his decision to resign as Chief Commercial Officer, effective August 28, 2026. The company states that he left to join a pre-commercial company and that the resignation does not follow any disagreement. The timing matters only because the commercial organisation is the part of the business the IBSRELA guidance cut placed under scrutiny. Source

Michael Raab has served as Ardelyx’s President and Chief Executive Officer since March 2009. His background includes seven years as a partner at New Enterprise Associates (2002–2009) and fifteen years of commercial and operating roles before that, including Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme, a renal background that, in Merlintrader’s reading, is relevant to a dialysis product. The 2026 proxy also notes that he chaired the board of Amicus Therapeutics from March 2024 until its acquisition by BioMarin in April 2026. That background is relevant because Ardelyx’s current phase requires both biotech persistence and commercial discipline. The company’s XPHOZAH path demanded regulatory persistence; the current IBSRELA phase demands launch execution and cost control.

Governance is now a practical issue for shareholders. Ardelyx is no longer a small research company waiting for a single decision. It is scaling a commercial organization, running Phase 3 work, managing debt, issuing equity compensation and making capital allocation decisions. The board and management team have to balance growth with per-share discipline. For retail investors, the key governance questions are simple: are incentives aligned with durable shareholder value, is dilution controlled, and is management honest about reimbursement friction and operating leverage?

The latest Form 4 filings, dated August 25, report August 21 automatic sales to cover RSU withholding taxes. Michael Raab sold a total of 58,574 shares at a weighted-average $3.8569 across four entries. The footnotes identify mandatory tax coverage, not a discretionary bearish decision. Related Form 144 notices are not additional completed sales. Across all eight officers who filed that day, the automatic sales total 126,059 shares, about $0.49 million at the reported price (Merlintrader calculation), including 8,562 shares for Eric Foster a week before his departure. The last sale on file not tied to tax withholding is Mr. Raab’s July 15, 2026 sale of 41,668 shares at a weighted-average $5.062, executed under a 10b5-1 trading plan adopted on November 7, 2025. Forms 4 on EDGAR →

The June update adds one more governance angle. Ardelyx’s 2026 proxy process placed the equity incentive reserve directly in front of shareholders, and the company argued that expanded equity capacity was needed to support commercial momentum, pipeline development and talent retention through 2027. That is understandable for a growing commercial biotech, but it also belongs in the ARDX risk checklist because per-share value is not determined only by revenue growth. If equity awards expand while the company remains loss-making, shareholders need to monitor whether the compensation structure is helping build durable value or simply increasing the diluted share base.

The 2026 annual meeting converted the equity-plan proposal into approved capacity. Shareholders authorized 9.0 million additional shares for the incentive-plan reserve, with 77.4 million votes for and 69.7 million against. The relatively close vote does not invalidate the approval, but it shows that a meaningful portion of voting shareholders was uncomfortable with the request: the votes for were about 52.6% of the votes cast for or against (Merlintrader calculation on the June 17 Form 8-K). The proxy put the projected overhang at about 26.3% after the increase and disclosed annual equity burn rates of 5.2%, 7.2% and 8.3% for 2023, 2024 and 2025. The 9,000,000 new shares were registered on a Form S-8 on August 10, 2026. At June 30 the company had 29.3 million options outstanding at a weighted-average exercise price of $5.76 and 15.3 million unvested restricted stock units, together equal to about 17.9% of the 249.2 million shares outstanding on July 30 (Merlintrader calculation on 10-Q data). The central governance question is now whether future awards support retention and execution while remaining proportionate to per-share value creation.

Two large holders reported positions at the end of the second quarter. Rubric Capital Management and David Rosen filed a Schedule 13G on August 14, 2026 reporting 16,202,700 shares, 6.56% of the class, as of June 30; Millennium Management entities filed an amended Schedule 13G on August 11 reporting 14,200,773 shares, 5.7%, as of the same date. These filings describe passive positions at a past date and say nothing about later trading. Short sellers are also present: Nasdaq reported short interest of 25,602,541 shares at the September 15, 2026 settlement date, about 10.3% of shares outstanding (Merlintrader calculation) and 6.3 days of average volume. Rubric 13G → Millennium 13G/A → Nasdaq short interest →

20 XPHOZAH Policy and Reimbursement: The Part of the Story Traders Cannot Ignore

On June 26, 2026 the D.C. Circuit affirmed dismissal of the CMS reimbursement lawsuit. Ardelyx said it would not pursue further litigation on this matter. This closes that litigation route; it does not guarantee future policy change or establish why management withdrew long-term XPHOZAH guidance.

This matters because it helps explain why XPHOZAH should not be judged only by clinical differentiation. A product can be mechanistically differentiated and still face a difficult adoption curve if the reimbursement structure changes the incentives of dialysis providers, patients and payers. Ardelyx has continued to report paid-prescription activity, but the 2025 revenue reset shows that reimbursement can materially affect reported sales.

For an ARDX watchlist, XPHOZAH should therefore be followed through four lenses: paid prescriptions, non-Medicare utilization, management’s access commentary and any regulatory or policy developments affecting phosphate-lowering therapies in dialysis. A cleaner reimbursement environment would strengthen the bull case. Continued friction would leave IBSRELA carrying most of the growth burden.

21 Red Flags and What to Monitor

Operating leverage: revenue is growing, but losses and SG&A remain large. Investors should watch whether each incremental revenue dollar begins to carry more margin. If spending continues rising too closely with sales, the market may keep discounting the story.

XPHOZAH access: the product’s clinical rationale is not the same as its reimbursement path. Any deterioration in coverage, dialysis-provider economics or patient affordability could limit growth even if nephrologists understand the mechanism.

Gross-to-net complexity: Ardelyx’s filings make clear that net product revenue depends on estimates for discounts, rebates, chargebacks, copay assistance and returns. Changes in payer mix can alter the quality of reported revenue.

Debt and interest expense: the June 29 Term F draw increased contractual principal under the SLR facility from $200.0 million at March 31 to $250.0 million after the draw. The variable-rate debt improves liquidity flexibility but increases fixed financial obligations and secured-creditor risk. The covenant ties the facility to trailing product revenue, so a weaker revenue run-rate would tighten it even with no change in cash.

Dilution and equity compensation: stock-based compensation is meaningful, and shareholders approved 9.0 million additional shares for the incentive-plan reserve. This is not immediate issuance, but it increases potential future dilution.

Securities litigation: the Broadwater complaint covers a class period of more than eighteen months and names current and former executives. Earlier securities and derivative cases against Ardelyx ended in dismissal, but each case is decided on its own record, and defense costs, management time and any settlement would fall on the same cash balance that funds the commercial effort.

Clinical timing: ACCEL is important, but topline data are expected in the second half of 2027. Any enrollment delay, endpoint miss or weak commercial read-through could pressure sentiment before the program creates value.

August 6 guidance risk: because ARDX is now a commercial execution name, any slowdown in IBSRELA, weakness in XPHOZAH, higher-than-expected cash use or cautious commentary on ACCEL and RDX10531 could move the stock even without a binary regulatory event.

22 Merlintrader Bottom Line

ARDX is not a simple approval-pending biotech. It is a commercial-stage company trying to prove that tenapanor can support a durable business across gastrointestinal and renal markets. That makes the story better in some ways and harder in others. Better, because Ardelyx has approved products, real revenue and clinical expansion optionality. Harder, because investors can now judge the company every quarter on commercial execution, reimbursement, cost discipline, debt and per-share value creation.

The cleanest bullish argument remains IBSRELA. The product has delivered rapid growth, management has set ambitious long-term targets, and ACCEL could broaden the opportunity if the Phase 3 program succeeds. The main counterargument is that growth remains expensive, XPHOZAH is structurally exposed to reimbursement, the company is still loss-making and the June debt draw raises the financial hurdle.

The scheduled Cantor September 10 and Morgan Stanley September 16 appearances are past events. The central watchlist is conversion of IBSRELA prescriptions into paid revenue, revised guidance, costs, debt and ACCEL execution. The August earnings report is already historical. The next dated items are the November 16 lead-plaintiff deadline, a procedural step, and the December 20 deadline to draw the optional Term G loan; the third-quarter report has no announced date as of October 5, 2026.

A stronger quarter would not eliminate reimbursement, dilution or debt risk. A weak quarter would not erase the value of two approved products. The more useful framework is to watch whether product growth, operating leverage and capital discipline begin moving in the same direction. That alignment is what can change the quality of the ARDX valuation over time.